CDEK
← All drugs Report issue

nicorandil

Small moleculeexperimental

Nicorandil is a vasodilator drug used to treat angina, which is chest pain that results from episodes of transient myocardial ischemia. Angina can be caused by diseases such as atherosclerosis, coronary artery disease, and aortic stenosis. — Wikipedia

Clinical trial activity

32 trials · 41 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
6
Phase 3
3
Phase 4
18

Earliest trial started Oct 1, 2001 (NCT00212030)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(NCCO[N+](=O)[O-])c1cccnc1
Mol. weight
211.18 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-nicotinamidoethyl nitrate
  • 2-nicotinamidoethyl nitrate
  • brn 0481451
  • brn 0481451
  • ikorel
  • ikorel
  • n-(2-hydroxyethyl)nicotinamide nitrate
  • n-(2-hydroxyethyl)nicotinamide nitrate
  • n-(2-hydroxyethyl)nicotinamide nitrate (ester)
  • n-(2-hydroxyethyl)nicotinamide nitrate (ester)
  • nicorandil
  • nicorandil
  • nicorandil
  • nicorandil
  • nicorandil
  • nicorandil
  • nicorandil
  • nicorandil
  • nicorandilum
  • nicorandilum
  • perisalol
  • sg-75
  • sg-75
  • sg-75
  • sigmart

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06787430Phase 4Feb 1, 2025Chinese Academy of Medical Sciences
NCT06423729Phase 2/Phase 3 (Phase 3)Jun 1, 2024Tanta University
NCT07138508Phase 1/Phase 2 (Phase 2)Mar 10, 2024Ain Shams University, Misr University for Science and Technology
NCT06249581Early Phase 1 (Phase 1)Nov 27, 2023Auxilius Pharma, Blueclinical, Ltd.
NCT06430125Phase 3Feb 28, 2023Tanta University
NCT05427786Phase 4Dec 14, 2022Korea University
NCT05399576Phase 2May 17, 2022Zhejiang Chinese Medical University
NCT04826497Phase 4Apr 30, 2021Shanghai Xuhui District Central Hospital, Southeast University
NCT04665648Phase 4Jan 1, 2021Fudan University
NCT04310995Phase 4May 31, 2020Chugai, Jiao Tong University
NCT04120766Phase 2Dec 1, 2019University of Kentucky
NCT05087797Phase 4Apr 8, 2019Peking University
NCT03775902N/ADec 19, 2018University of Copenhagen
NCT03445728Phase 4Feb 24, 2018People's Liberation Army of China
NCT03252665Phase 4Sep 1, 2017Huazhong University of Science and Technology, Jiao Tong University
NCT04646278N/AApr 11, 2017KangWon National University, The Korean Society of Cardiology
NCT03235700N/AMar 1, 2017Sejong General Hospital
NCT03010423Phase 4Nov 30, 2016Merck KGaA, Merck Serono
NCT02809456Phase 2Jul 1, 2016Taipei Medical University
NCT02449070Phase 3May 1, 2015JW Pharmaceutical, Pusan National University
Showing 20 of 32 trials
Page 1 / 2

Organizations

Research & Development (41)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Merck KGaAFor profit3312011
Merck SeronoFor profit3012011
Jiao Tong UniversityAcademic/Hospital2212017
People's Liberation Army of ChinaGovernment2112014
Shanghai Xuhui District Central HospitalAcademic/Hospital2212015
Southeast UniversityAcademic/Hospital2012015
Tanta UniversityAcademic/Hospital2212023
Aarhus UniversityAcademic/Hospital1112007
Ain Shams UniversityAcademic/Hospital1112024
Auxilius PharmaFor profit1112023
Blueclinical, Ltd.For profit1012023
Chinese Academy of Medical SciencesAcademic/Hospital1112025
ChugaiFor profit1012020
Danish Cardiovascular Research AcademyAcademic/Hospital1012007
Danish Heart FoundationAcademic/Hospital1012007
Ferozsons Laboratories Ltd.For profit1112011
Fudan UniversityAcademic/Hospital1112021
General ElectricFor profit1012010
Huazhong University of Science and TechnologyAcademic/Hospital1012017
Inje UniversityAcademic/Hospital1012011
41 organizations
Page 1 / 3